Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C M Kessler

Showing results (131-140 of 145) with videos related to

Pageof 15
Sort By:
Journal of the American College of Cardiology|July 1, 1992
Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trialS Z Goldhaber, C M Kessler, J A Heit, et al.
Lancet (London, England)|October 18, 1986
Acute pulmonary embolism treated with tissue plasminogen activatorS Z Goldhaber, D E Vaughan, J E Markis, et al.
Journal of Thrombosis and Haemostasis : JTH|June 19, 2013
Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approachJ M Kittelson, A C Spyropoulos, J L Halperin, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 5, 2016
Von Willebrand factor for menorrhagia: a survey and literature reviewM V Ragni, N Machin, L M Malec, et al.
Blood|May 1, 1995
Randomized study of didanosine monotherapy and combination therapy with zidovudine in hemophilic and nonhemophilic subjects with asymptomatic human immunodeficiency virus-1 infection. AIDS Clinical Trial GroupsM V Ragni, D A Amato, M L LoFaro, et al.
The Journal of Infectious Diseases|July 1, 1995
Human immunodeficiency virus (HIV) type 1 infection status and in vitro susceptibility to HIV infection among high-risk HIV-1-seronegative hemophiliacsM M Lederman, J B Jackson, B L Kroner, et al.
British Journal of Haematology|September 1, 1996
Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Cooperative Study GroupsD Menache, D L Aronson, F Darr, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 11, 2004
Liver biopsy in patients with inherited disorders of coagulation and chronic hepatitis CD Theodore, M W Fried, D E Kleiner, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 20, 2012
Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia AC L Kempton, T C Abshire, R A Deveras, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 19, 2017
Self-reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (P-FiQ) studyM Witkop, A Neff, T W Buckner, et al.
Pageof 15

Showing results (131-140 of 145) with videos related to

Sort By:
Pageof 15
Journal of the American College of Cardiology|July 1, 1992
Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trialS Z Goldhaber, C M Kessler, J A Heit, et al.
Lancet (London, England)|October 18, 1986
Acute pulmonary embolism treated with tissue plasminogen activatorS Z Goldhaber, D E Vaughan, J E Markis, et al.
Journal of Thrombosis and Haemostasis : JTH|June 19, 2013
Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approachJ M Kittelson, A C Spyropoulos, J L Halperin, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 5, 2016
Von Willebrand factor for menorrhagia: a survey and literature reviewM V Ragni, N Machin, L M Malec, et al.
Blood|May 1, 1995
Randomized study of didanosine monotherapy and combination therapy with zidovudine in hemophilic and nonhemophilic subjects with asymptomatic human immunodeficiency virus-1 infection. AIDS Clinical Trial GroupsM V Ragni, D A Amato, M L LoFaro, et al.
The Journal of Infectious Diseases|July 1, 1995
Human immunodeficiency virus (HIV) type 1 infection status and in vitro susceptibility to HIV infection among high-risk HIV-1-seronegative hemophiliacsM M Lederman, J B Jackson, B L Kroner, et al.
British Journal of Haematology|September 1, 1996
Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Cooperative Study GroupsD Menache, D L Aronson, F Darr, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 11, 2004
Liver biopsy in patients with inherited disorders of coagulation and chronic hepatitis CD Theodore, M W Fried, D E Kleiner, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 20, 2012
Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia AC L Kempton, T C Abshire, R A Deveras, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 19, 2017
Self-reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (P-FiQ) studyM Witkop, A Neff, T W Buckner, et al.
Pageof 15